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Abstract
Background: Injectable radioactive iodine (I-131) frequently is used to treat hyperthy-
roidism in cats. In human medicine, residual activity after injection of radionuclides has
been reported, and the actual quantity administered is recorded after administration.
Objective: Our aim was to evaluate actual administered dose variability after administra-
tion of preprepared I-131 single unit doses for the treatment of hyperthyroidism in cats.
Animals: Twenty-seven cats with hyperthyroidism treated with I-131 between April
2017 and March 2019.
Methods: Retrospective observational study of cats treated with preprepared single
unit I-131 doses. For each dose, the measured activity before administration and
residual activity were recorded. The measured dose and the actual dose administered
were compared to the prescribed dose.
Results: Measured activity before administration ranged from 88.4% to 103.3% of the
prescribed dose. Mean residual activity was 5.2 ± 3.0 MBq (ranging from 1.5% to 15%
of the prescribed dose). The actual dose administered (measured activity  residual
activity) ranged from 79.1% to 100.2% of the prescribed dose. Seventeen of 28 (60.7%)
of the actual administered doses differed between 10% and 20% of the prescribed dose.
One administered dose had a >20% difference compared to the prescribed dose
(79.10% of the prescribed dose).
Conclusion and Clinical Importance: Our study identified variability in the residual
and actual administered activity of I-131 as compared to the prescribed dose, which
should be taken into consideration when treating cats with (predrawn) I-131.
K E YWORD S
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1 | INTRODUCTION
Hyperthyroidism is the most commonly diagnosed endocrine disorder
in older cats and generally is caused by benign adenomatous disease
of the thyroid gland (or rarely thyroid carcinoma).1-5 Radioactive
iodine has been reported to be a safe and effective treatment, with a
>95% success rate after a single treatment for cats with mild-to-mod-
erate hyperthyroidism.4,6-13
Different doses have been reported in the veterinary literature
for the treatment of hyperthyroidism in cats, ranging from 1.5 to
40 mCi (55.5-1480 MBq).4,6,7,9-12,14-17 The required dose can be pre-
pared on-site or individual radioactive iodine (I-131) unit doses can be
Received: 25 November 2020 Accepted: 18 May 2021
DOI: 10.1111/jvim.16185
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2021 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
J Vet Intern Med. 2021;1–6. wileyonlinelibrary.com/journal/jvim 1
ordered from a centralized radionuclide pharmacy. In human medicine,
it has been estimated up to 80% of radiopharmaceutical doses in the
United States are dispensed by a central radionuclide pharmacy.18
Considerations for this central approach include cost-effectiveness,
increased quality control of radiopharmaceuticals, and pressure to
decrease man power within health care institutions.18,19 This option
may be suitable for veterinary practices where no controlled area is
available to allow for the safe preparation of radiopharmaceuticals
such as I-131. Furthermore, single unit doses can be a cost-effective
alternative if only a small number of patients is treated.
In human medicine, it is recognized that, for logistical reasons such as
postinjection residual activity, considerable variation may occur between
the prescribed and administered activity of radiopharmaceuticals.20-35 This
variation potentially can lead to inadequate dosing and treatment failure.
Several local guidelines and consensus statements for human patients
were consulted to identify recommendations regarding acceptable dose
discrepancies between the prescribed and administered dose in nuclear
medicine.20,21,28,34 Based on these local guidelines, the dispensed, mea-
sured, and administered quantity of radioactivity is recommended to be
within 10%, 5% to 10%, and 10% to 20% of the prescribed activity,
respectively.20,21,28,34 No such guidelines exist in veterinary medicine and,
despite wide use clinically, dose variability after I-131 administration has
not been evaluated in veterinary medicine.
The standard practice at our facility since 2017 was derived from
the standard practice at the regional human hospital. After publication
of the most recent local guidelines for humans, cases were reviewed
retrospectively to assess if the current standards of care for cats
treated with I-131 at our institution were in line with the nuclear
safety guidelines and recommendations used in humans.20,21,28,34
Our primary objective was to obtain data on dose activity variability
of the actual administered dose of I-131 as compared to the prescribed
activity and to assess at which level in the workflow the discrepancies
occurred. We hypothesized the variability would be within 20% of the
prescribed activity as recommended by guidelines used for human
patients. Discrepancies between the prescribed and administered dose
were suspected to occur mainly because of prepatient factors.
2 | MATERIALS AND METHODS
2.1 | Study design
A retrospective observational study was conducted to investigate
administered dose variability after treatment with I-131 unit doses.
2.2 | Patient selection
The electronic medical records of all cats treated with I-131 unit
doses at the Massey University Veterinary Teaching Hospital
(MUVTH), between April 2017 and March 2019 were reviewed. For
each patient, the prescribed I-131 dose, measured activity before
injection, and residual I-131 activity in the syringe were evaluated.
2.3 | Unit doses
All I-131 unit doses were purchased from a single provider. The
doses were ready to inject, and the dose activity was calibrated by the
provider for the time and date of treatment. The required volume was
delivered in predrawn disposable syringes. In all cases, a 3-mL plastic
syringe with an attached 23-gauge needle was used. The doses were
prepared by a distant pharmacy on Mondays. After arrival at our facil-
ity, the I-131 unit doses were stored at room temperature in the pro-
vided lead container until the time of treatment.35
The provider guaranteed that the activity of the unit doses dif-
fered by <10% from the ordered activity at the exact time and date of
treatment. Before administration to the patient, the activity of the I-
131 unit doses was determined using a dose calibrator. Assessment of
the doses before treatment was performed at the scheduled day and
time of administration (Thursdays at 12.00 pm).
The I-131 unit dose analysis was performed using a radioactivity
calibration system (ATOMLAB 100 plus dose calibrator, Biodex Medical
Systems Inc,Shirley,New York) inMBqimmediatelybeforeadministration.
The clear plastic chamber well liner was placed into the chamber
well and the plastic sample holder was lowered into the liner. The
3-mL plastic syringe containing the I-131 unit dose was carefully
placed into the sample holder using tongs, and then both were placed
into the chamber well, near the center of the chamber. A background
measurement was performed before each activity reading.
2.4 | Handling
The syringe and solution were inspected visually for particulate matter
and discoloration before each administration. The radioactive iodine
was administered SC in a shaved area on the left flank in all cats after
assessment of the measured dose. For 1 patient, a second I-131 unit
dose was ordered and administered because of failure to administer
the original dose correctly. Cats were not sedated for the I-131 admin-
istration. Residual dose measurements after administration were per-
formed as described above, immediately after injection. All cats were
housed in isolation for 14 days after treatment.
A radiopharmaceutical record was maintained that included batch
number, time, date, patient name and number, name of the clinician
administering the dose, prescribed dose, calculated dose, measured
activity before injection, residual activity, and actual administered activ-
ity as defined in Table 1. The number of doses for which the measured
dose differed >10% from the prescribed dose and the number of
administrations for which the actual administered dose differed by
>20% from the prescribed dose were recorded. Results were compared
to the previously described recommendations for humans.20,21,28,34
A Code of Safe Practice has been produced by the Office of Radi-
ation Safety (ORS) to ensure the safe use of I-131 for treatment of
cats with thyroid disorders using radioactive iodine (I-131).35 Both
users of radioactive materials had an appropriate license under the
Act for the purpose of Veterinary Therapy under the Radiation Pro-
tection Act 1965.
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2.5 | Statistical analysis
Descriptive statistics were performed. The actual administered and
residual activity were calculated as defined in Table 1.
3 | RESULTS
All I-131 unit doses administered as treatment for cats with hyperthy-
roidism during the study period were included in the study. Twenty-
eight I-131 unit doses were administered to 27 cats during the study
period at the scheduled day and time of administration.
A fixed dose of 100 MBq calculated for the time of calibration
(Thursday 12.00 pm) was ordered for 23 patients. For 1 patient, a sec-
ond dose of 100 MBq was ordered because of misadministration of
the original dose. For 2 patients, a lower dose of 75 MBq was
ordered, based on the scoring system for selection of the I-131 dose
as described previously and based on relatively mildly increased serum
total thyroxine concentrations (44.0 nmol/L and 60.9 nmol/L, respec-
tively; reference range, 10.4-42.0 nmol/L) measured before treat-
ment.4,6,13 A higher dose of 115 MBq was ordered for 2 cats with
serum total thyroxine concentrations of 223.90 nmol/L and
483.0 nmol/L, respectively.
The total dose calculated by the provider ranged from 75 to
122 MBq (mean ± SD, 100.5 ± 8.5 MBq). The measured activity of
the I-131 unit doses ranged between 66.7 and 111 MBq (mean ± SD,
93.3 ± 8.2 MBq). The measured activity before administration ranged
from 88.4% to 103.3% of the prescribed dose, and 5 of 28 samples
(17.9%) differed between 10% and 20% from the prescribed activity
(mean ± SD, 6.1% ± 3.5%) at the time of administration.
TABLE 1 Definitions
Definitions
Unit dosage Dosage prepared for medical use for
administration as a single dosage to a patient
without further manipulation of the dosage
after it is initially prepared28
Prescribed dose The intended and ordered activity as specified
by the authorized clinician
Calculated dose The activity calculated by the nuclear pharmacy
for the time and date of administration
Measured dose The activity measured in the on-site dose
calibrator, immediately before administration
Residual syringe
dose
The remaining activity in the syringe was
measured, and the percentage of residual
activity was calculated using the following
equation:
Residual activity %ð Þ¼ Residual activity MBqð ÞMeasured activity MBqð Þ100
Actual administered
dose
Administered dose (MBq) = measured
activity (MBq) residual activity (MBq)
Administered dose %ð Þ¼ Administered activity MBqð ÞPrescribed activity MBqð Þ 
100
TABLE 2 Possible sources of administered dose variability (adjusted from Ref. 28)
Source of dose variability Variability
Prescribed/ordered dosage
#
Dosage calculated by compounding nuclear
pharmacy to account for radiochemical
breakdown during transport and storage
Human error
#
Unit-dose preparation Technique/human error Unknown
#
Measured dosage Calibrator accuracy
Variations in geometry within the chamber
Difference between the dosage calibration time and dosage
administration time
Volume of the patient dose
Storage temperature and material
% of prescribed dosage
±5% 21,28 to 10% 20 a
#
Residual activity Syringe-Needle Dead space volume
Syringe type
Properties of the radiopharmaceutical
Injection technique/care and awareness
Adsorption to Vessel Wall
Retention time
Demeanor of the patient
Approximately up to 6%28
#
Administered dosage % of prescribed dose
±10%28 to 20%34 a
aRecommended maximum.
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The postinjection residual activity in the syringe was measured
immediately after administration and ranged from 1.5 to 15 MBq
(mean ± SD, 5.2 ± 3.0 MBq) corresponding to 1.5% to 15% of the pre-
scribed dose (mean ± SD, 5.2 ± 2.9 MBq).
The administered dose ranged between 79.1% and 100.2% of the
prescribed dose (mean ± SD, 88.80% ± 4.4%). For 60.7% of the admin-
istrations (17/28), the actual dose administered differed between 10%
and 20% from the prescribed dose. One cat (3.6%) received a dose
that differed by >20% of the prescribed dose (79.1% of the pre-
scribed dose).
4 | DISCUSSION
Syringe activity before administration and residual activity are not
standardly reported in the veterinary literature. Instead, dosing recom-
mendations generally are based on the intended I-131 dose (the pre-
scribed activity) and the expected clinical outcome.
In human medicine, it is recognized that there may be a consider-
able variation between the prescribed activity and the actual adminis-
tered activity of radionuclides. Verification of the administered
activity by means of a dose calibrator is recommended to ensure the
total activity does not deviate substantially from the prescribed activ-
ity, and the measured value should be recorded.21 Consensus recom-
mendations on the activity difference that is considered substantially
different appear to be lacking.
In our study, the actual administered dose ranged from 64.3 to
100.22 MBq and, in 64.3% of patients, the actual administered dose
was >10% lower than the prescribed dose. Several possible sources of
dose variability during different stages of dose delivery have been
considered (Table 2).
Postinjection residual activity has been reported for various
drugs, including several radiopharmaceuticals. The residual activity is
generally small at 1% to 9%, but some reports suggest residual activity
can reach levels up to 80% for specific radionuclides.22-25,32,33 In addi-
tion to an expected dead space residual volume, storage temperature,
storage material, plunger type, and retention time in the syringe have
been described to affect the residual activity.25,32,33,36 Because of
the logistics of delivery, residence time in the syringe was substantial
during our study (>48 hours). Iodination of plastic vials used for
shipping of I-131 capsules previously has been reported, with I-131
activity of the plastic container ranging from 0.5% to 2.4% of the total
activity in the vial measured 1 day before calibration.26 The results
indicated that measurements of capsule activity in the plastic vials
used for storage may lead to overestimation of the administered dose,
especially for capsules that have been stored for several days.26,27
The average residual activity in our study was 5.2% of the prescribed
dose. Further assessment of the effect of the residence time and
the material of the syringe on the residual activity of I-131 could be
valuable and would add to our understanding of I-131 dosing.
In addition to the prepatient factors, the behavior of the cats
could have affected the actual administered dose variability in our
study, because I-131 administration was performed in conscious
animals with different behavior and temperaments. Administration of
I-131 unit doses in sedated patients potentially could improve repeat-
ability and minimize this aspect of the dose variability.
Our study was initiated based on guidelines for humans and we
hypothesized that similar dose variability could exist in cats. Consider-
ations that should be taken into account include a different method of
administration. Encapsulated I-131 is the primary treatment form in
human health care, whereas liquid I-131 is used for PO administration
in selected cases.20,37 The SC administration of I-131 differs from the
PO administration of I-131 using capsules, where syringes are used to
fill the capsules in a controlled environment. Furthermore, because of
the geographical location of our institution, there was a prolonged
retention time in the syringe, which could have contributed to the
residual activity.
Although information on the residual activity and injection
technique in veterinary medicine is limited, we assume other stud-
ies, including those used for I-131 dose references, might have
encountered similar issues during workflow leading to discrepan-
cies between the prescribed and actual administered dose.
Although the actual administered dose may be lower than assumed
based on the published prescribed dose recommendations, for most
patients the anticipated therapeutic end point is achieved with
>95% of cats reported to have normal serum thyroid hormone con-
centrations by 3 to 6 months after treatment.6,9 In recent years,
even lower doses of I-131 have been described in the veterinary lit-
erature with possible benefits including lower radiation exposure to
the patient and personnel, decreased incidence of iatrogenic hypo-
thyroidism, and decreased costs.6,38 Future studies investigating
discrepancies between prescribed and actual administered doses
and possible issues encountered during the workflow could add to
our current understanding and further optimize I-131 dosing and
administration recommendations for the treatment of hyperthy-
roidism in cats.
Our study had several limitations. The main limitations were the
retrospective nature of the study and the small sample size. Further-
more, the calibration, administration, and measurement of the residual
dose were performed by 2 clinicians. However, the injection tech-
nique and measurements were performed according to an identical
protocol. Another limitation was caused by the fact that each sample
was measured only once at each timepoint, because the exposure was
meant to be limited in accordance with the “As Low As Reasonably
Achievable” (ALARA) principle.39
Discrepancies in dose calibrator assays among various packagings
of I-131 have been reported in the literature.40 All I-131 doses in our
study were prepared by a single supplier, prescribed across a narrow
dose range, and therefore consisted of a narrow range of volumes. In
addition, all doses were provided in a single size and type of syringe
and needle. Therefore, our data should be interpreted with care and
the ability to extrapolate this data to other settings might be limited.
Moreover, long-term outcomes of dose variability between the
prescribed and actual administered dose could not be evaluated, and
prospective, longer-term studies are required to evaluate possible
long-term consequences.
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The potential radiation hazard to staff is the main disadvantage of
I-131 treatment. The use of I-131 unit doses can be a safer and more
cost-effective option for certain practices that treat veterinary patients
with hyperthyroidism. Therefore, our intent is not to discourage use of
I-131 unit doses, but rather to investigate potential dose variabilities
that may occur when using this treatment modality in practice because
this issue concerning the treatment of hyperthyroidism in cats has not
been reported previously in the veterinary literature.
5 | CONCLUSION
Our study raises several points of concern regarding variability in the
actual administered activity when treating cats with I-131 unit doses.
Based on our results, residual dose assessment is recommended as part
of routine quality control. In addition, it is postulated that actual admin-
istered activity and not only preinjection syringe activity should be con-
sidered when evaluating patient response after treatment. However,
additional studies are required to confirm this data and investigate pos-
sible long-term consequences of dose variability. A better understand-
ing of the administered dose activity could help to increase awareness
of possible dose variability, improve quality control and radiation safety,
recognize reasons for an unexpected treatment response, and optimize
the dose and administration technique in cats.
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